Characterization and Evaluation of Bone-Derived Nanoparticles as a Novel pH-Responsive Carrier for Delivery of Doxorubicin into Breast Cancer Cells

被引:10
|
作者
Haque, Sheikh Tanzina [1 ]
Islam, Rowshan Ara [1 ]
Gan, Siew Hua [2 ]
Chowdhury, Ezharul Hoque [1 ,3 ]
机构
[1] Monash Univ Malaysia, Jeffrey Cheah Sch Med & Hlth Sci, Jalan Lagoon Selatan, Subang Jaya 47500, Selangor, Malaysia
[2] Monash Univ Malaysia, Sch Pharm, Jalan Lagoon Selatan, Subang Jaya 47500, Selangor, Malaysia
[3] Monash Univ Malaysia, Trop Med & Biol Multidisciplinary Platform, Jalan Lagoon Selatan, Subang Jaya 47500, Selangor, Malaysia
关键词
goose bone ash (GBA); carbonated apatite; breast cancer; carbonate apatite (CA); pH responsive drug delivery; cytotoxicity; cellular uptake; DOX binding; protein corona; nano-carrier; CARBONATE APATITE; CONTROLLED-RELEASE; DRUG-DELIVERY; PROTEIN CORONA; NANO-CRYSTALS; DESIGN; HYDROXYAPATITE; ADSORPTION; LIPOSOMES; SIZE;
D O I
10.3390/ijms21186721
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: The limitations of conventional treatment modalities in cancer, especially in breast cancer, facilitated the necessity for developing a safer drug delivery system (DDS). Inorganic nano-carriers based on calcium phosphates such as hydroxyapatite (HA) and carbonate apatite (CA) have gained attention due to their biocompatibility, reduced toxicity, and improved therapeutic efficacy.Methods: In this study, the potential of goose bone ash (GBA), a natural derivative of HA or CA, was exploited as a pH-responsive carrier to successfully deliver doxorubicin (DOX), an anthracycline drug into breast cancer cells (e.g., MCF-7 and MDA-MB-231 cells). GBA in either pristine form or in suspension was characterized in terms of size, morphology, functional groups, cellular internalization, cytotoxicity, pH-responsive drug (DOX) release, and protein corona analysis.Results: The pH-responsive drug release study demonstrated the prompt release of DOX from GBA through its disintegration in acidic pH (5.5-6.5), which mimics the pH of the endosomal and lysosomal compartments as well as the stability of GBA in physiological pH (pH 7.5). The result of DOX binding with GBA indicated an increment in binding affinity with increasing concentrations of DOX. Cell viability and cytotoxicity analysis showed no innate toxicity of GBA particles. Both qualitative and quantitative cellular uptake analysis in both cell lines displayed an enhanced cellular internalization of DOX-loaded GBA compared to free DOX molecules. The protein corona spontaneously formed on the surface of GBA particles exhibited its affinity toward transport proteins, structural proteins, and a few other selective proteins. The adsorption of transport proteins could extend the circulation half-life in biological environment and increase the accumulation of the drug-loaded NPs through the enhanced permeability and retention (EPR) effect at the tumor site. Conclusion: These findings highlight the potential of GBA as a DDS to successfully deliver therapeutics into breast cancer cells.
引用
收藏
页码:1 / 27
页数:26
相关论文
共 50 条
  • [31] Polymeric mesoporous silica nanoparticles as a pH-responsive switch to control doxorubicin intracellular delivery
    Tian, Ye
    Glogowska, Aleksandra
    Zhong, Wen
    Klonisch, Thomas
    Xing, Malcolm
    JOURNAL OF MATERIALS CHEMISTRY B, 2013, 1 (39) : 5264 - 5272
  • [32] Novel pH-responsive multilayer magnetic nanoparticles for controlled drug delivery
    Seyed Farshad Motevalizadeh
    Mehdi Khoobi
    Niloofar Babanejad
    Elham Mohit
    Pouya Dehghankelishadi
    Hamid Akbari Javar
    Farid A. Dorkoosh
    Mohammad Ali Faramarzi
    Abbas Shafiee
    Journal of the Iranian Chemical Society, 2016, 13 : 1653 - 1666
  • [33] Green and facile synthesis of highly biocompatible carbon nanospheres and their pH-responsive delivery of doxorubicin to cancer cells
    Liu, Xiaoli
    Jiang, Hui
    Ge, Wei
    Wu, Changyu
    Chen, Donghua
    Li, Qiwei
    Chen, Yun
    Wang, Xuemei
    RSC ADVANCES, 2015, 5 (23): : 17532 - 17540
  • [34] Magnetic drug carrier with a smart pH-responsive polymer network shell for controlled delivery of doxorubicin
    Ma, Wan-Fu
    Wu, Ke-Yi
    Tang, Jing
    Li, Dian
    Wei, Chuan
    Guo, Jia
    Wang, Shi-Long
    Wang, Chang-Chun
    JOURNAL OF MATERIALS CHEMISTRY, 2012, 22 (30) : 15206 - 15214
  • [35] Novel pH-responsive multilayer magnetic nanoparticles for controlled drug delivery
    Motevalizadeh, Seyed Farshad
    Khoobi, Mehdi
    Babanejad, Niloofar
    Mohit, Elham
    Dehghankelishadi, Pouya
    Javar, Hamid Akbari
    Dorkoosh, Farid A.
    Faramarzi, Mohammad Ali
    Shafiee, Abbas
    JOURNAL OF THE IRANIAN CHEMICAL SOCIETY, 2016, 13 (09) : 1653 - 1666
  • [36] A photoluminescent folic acid-derived carbon dot functionalized magnetic dendrimer as a pH-responsive carrier for targeted doxorubicin delivery
    Karimi, Soheyla
    Namazi, Hassan
    NEW JOURNAL OF CHEMISTRY, 2021, 45 (14) : 6397 - 6405
  • [37] A new theranostic pH-responsive niosome formulation for doxorubicin delivery and bio-imaging against breast cancer
    Saharkhiz, Shaghayegh
    Zarepour, Atefeh
    Zarrabi, Ali
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2023, 637
  • [38] Biodegradable and Inherently Fluorescent pH-Responsive Nanoparticles for Cancer Drug Delivery
    Kalindu Perera
    Dat X. Nguyen
    Dingbowen Wang
    Aneetta E. Kuriakose
    Jian Yang
    Kytai T. Nguyen
    Jyothi U. Menon
    Pharmaceutical Research, 2022, 39 : 2729 - 2743
  • [39] Biodegradable and Inherently Fluorescent pH-Responsive Nanoparticles for Cancer Drug Delivery
    Perera, Kalindu
    Nguyen, Dat X.
    Wang, Dingbowen
    Kuriakose, Aneetta E.
    Yang, Jian
    Nguyen, Kytai T.
    Menon, Jyothi U.
    PHARMACEUTICAL RESEARCH, 2022, 39 (11) : 2729 - 2743
  • [40] Ginsenoside Rg3 Reduces the Toxicity of Graphene Oxide Used for pH-Responsive Delivery of Doxorubicin to Liver and Breast Cancer Cells
    Rahimi, Shadi
    van Leeuwen, Daniel
    Roshanzamir, Fariba
    Pandit, Santosh
    Shi, Lei
    Sasanian, Nima
    Nielsen, Jens
    Esbjoerner, Elin K.
    Mijakovic, Ivan
    PHARMACEUTICS, 2023, 15 (02)